|
Synonyms: AEVI-002 | AVTX-002 | CERC-002 | MDGN-002 | SAR-252067 | SAR252067 [3]
Compound class:
Antibody
Comment: Quisovalimab (AVTX-002) is a clinical stage, fully human IgG4 anti-LIGHT (TNFSF14) monoclonal antibody. It was developed for anti-inflammatory potential [3]. Quisovalimab binds to LIGHT and prevents it from interacting with its receptors on T cells [1].
As CERC-002, this agent was assessed for efficacy as a treament for COVID-19-related pneumonia and ARDS/acute lung injury, based on evidence of a pro-inflammatory effect of LIGHT on the interaction between T cells and airway smooth muscle cells [2]. |
| References |
|
1. Granger SW, Kato S, Ware CF. (2008)
Antagonistic human light-specific human monoclonal antibodies. Patent number: WO2008027338A2. Assignee: Kyowa Hakko Kirin Co., Limited, La Jolla Institute For Allergy And Immunology. Priority date: 28/08/2006. Publication date: 06/03/2008. |
|
2. Shi F, Xiong Y, Zhang Y, Qiu C, Li M, Shan A, Yang Y, Li B. (2018)
The Role of TNF Family Molecules Light in Cellular Interaction Between Airway Smooth Muscle Cells and T Cells During Chronic Allergic Inflammation. Inflammation, 41 (3): 1021-1031. [PMID:29460021] |
|
3. Zhang M, Perrin L, Pardo P. (2017)
A Randomized Phase 1 Study to Assess the Safety and Pharmacokinetics of the Subcutaneously Injected Anti-LIGHT Antibody, SAR252067. Clin Pharmacol Drug Dev, 6 (3): 292-301. [PMID:27545119] |
